Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10398)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PLK1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Responsed Drug | Tectoridin | Investigative | ||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
Cell proliferation | ||||
In Vitro Model |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
Response regulation | Tectoridin synergized with PLK1 inhibitor to suppress autophagy and ferroptosis but promoted caspase-3-mediated apoptosis in A549 (Lung adenocarcinoma) cells. Our findings highlight a potential drug target and the combination therapy strategy of PLK1 inhibitor and tectoridin for LUAD patients. In vitro experiments, we confirmed that tectoridin could inhibit the expression of PLK1. | |||
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Serine/threonine-protein kinase PLK1 (PLK1) | Protein coding | ||
Responsed Drug | Tectoridin | Investigative | ||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
Cell proliferation | ||||
In Vitro Model |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
Response regulation | Tectoridin synergized with PLK1 inhibitor to suppress autophagy and ferroptosis but promoted caspase-3-mediated apoptosis in A549 (Lung adenocarcinoma) cells. Our findings highlight a potential drug target and the combination therapy strategy of PLK1 inhibitor and tectoridin for LUAD patients. In vitro experiments, we confirmed that tectoridin could inhibit the expression of PLK1. | |||
Tectoridin
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Suppressor | |||
Response Target | Unspecific Target | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
Cell proliferation | ||||
In Vitro Model |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
Response regulation | Tectoridin synergized with PLK1 inhibitor to suppress autophagy and ferroptosis but promoted caspase-3-mediated apoptosis in A549 (Lung adenocarcinoma) cells. Our findings highlight a potential drug target and the combination therapy strategy of PLK1 inhibitor and tectoridin for LUAD patients. In vitro experiments, we confirmed that tectoridin could inhibit the expression of PLK1. | |||